^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
Excerpt:
...(2) Patients with an ALK gene rearrangement must have experienced disease progression or were intolerant to treatment with one or more ALK inhibitors, such as crizotinib, alectinib, ceritinib, brigatinib, ensartinib and lorlatinib that are appropriate for the treatment of NSCLC that has an ALK gene rearrangement....
Trial ID:
Source:
Title:
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Excerpt:
...Never smoker wild-types are defined as patients with tumors without an ALK or ROS1 rearrangement, and are...
Trial ID:
Less C2 evidence
Source:
Title:
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018
Published date:
01/29/2023
Excerpt:
Patients received platinum, pemetrexed, atezolizumab, bevacizumab (PPAB cohort)....EGFR mutation, 87.3%/89.7%; ALK rearrangement, 12.7%/5.1%; ROS1 fusion, 0%/6.4%, respectively)....After 12 weeks, objective response rate was 58.2% (90% confidence interval [CI], 47.4-68.4) in PPAB cohort and 46.5% (90% CI, 36.3-56.9) in PPA cohort. Median progression-free survival and overall survival were 7.3 (95% CI 6.9-9.0) months and 17.2 (95% CI 13.7-NA) months in PPAB cohort and 7.2 (95% CI 5.7-9.2) months and 16.8 (95% CI 13.5-NA) months in PPA cohort, respectively....Combination approach with atezolizumab with or without bevacizumab and platinum-pemetrexed achieved promising activity in metastatic EGFR-mutated or ALK/ROS1-rearranged NSCLC after tyrosine kinase inhibitor failure, with acceptable safety profile.
Secondary therapy:
Chemotherapy + pemetrexed
DOI:
https://doi.org/10.1016/j.ejca.2023.01.014
Trial ID:
Source:
Title:
1016P - GFPC 06-2018: A multicentre phase II, open-label, non-randomized study evaluating platinum-pemetrexed-atezolizumab (+/- bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies
Published date:
09/05/2022
Excerpt:
We conducted a national, open, multicentre, non-randomized Phase II Study with two parallel cohorts: A (Platinum-Pemetrexed-Atezolizumab-Bevacizumab) and B (Platinum-Pemetrexed-Atezolizumab). Main eligibility criteria were: stage IIIB/IV NSCLC with EGFR mutation or ALK/ROS1 rearrangement progression after ≥1 targeted therapy and no prior chemotherapy and eligible for Bevacizumab (A)....Combination approach of Platinum-Pemetrexed-Atezolizumab-Bevacizumab or Platinum-Pemetrexed-Atezolizumab achieved promising efficacy in metastatic EGFR/ALK mutated NSCLC after TKI failure, with acceptable tolerance profile.
Secondary therapy:
pemetrexed
Trial ID:
